Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Evolving insights into viral hepatitis : Advances, evidence, and expert perspectives from the ESCMID Study Group for Viral Hepatitis (ESGVH) – Part 2: hepatitis B, C, and delta

Săndulescu, Oana ; Matičič, Mojca ; Garcia, Federico ; Blomé, Marianne Alanko LU ; Mondelli, Mario U. ; Irving, William ; Zidovec-Lepej, Snjezana ; Widell, Anders LU and Şahin, Gülşen Özkaya LU (2025) In GERMS 15(3). p.263-273
Abstract

Hepatitis B virus (HBV), hepatitis delta virus (HDV), and hepatitis C virus (HCV) remain leading drivers of chronic viral hepatitis, cirrhosis, hepatocellular carcinoma, and liver-related mortality. This ESCMID Study Group for Viral Hepatitis (ESGVH) narrative review summarizes recent advances and expert perspectives in the field. For HBV, emerging biomarkers such as quantitative HBs antigen, HBV RNA, and hepatitis B core-related antigen offer opportunities to refine monitoring and to individualize treatment. HDV epidemiology is evolving, and is being increasingly studied; in parallel, the approval of bulevirtide represents a major breakthrough in therapy, with further agents in the HDV pipeline. For HCV, direct-acting antivirals... (More)

Hepatitis B virus (HBV), hepatitis delta virus (HDV), and hepatitis C virus (HCV) remain leading drivers of chronic viral hepatitis, cirrhosis, hepatocellular carcinoma, and liver-related mortality. This ESCMID Study Group for Viral Hepatitis (ESGVH) narrative review summarizes recent advances and expert perspectives in the field. For HBV, emerging biomarkers such as quantitative HBs antigen, HBV RNA, and hepatitis B core-related antigen offer opportunities to refine monitoring and to individualize treatment. HDV epidemiology is evolving, and is being increasingly studied; in parallel, the approval of bulevirtide represents a major breakthrough in therapy, with further agents in the HDV pipeline. For HCV, direct-acting antivirals provide curative therapy and have made elimination a realistic goal, while identifying remaining gaps in diagnosis, linkage-to-care, and equitable access offers clear opportunities to accelerate progress. Together, these advances bring the goal of a hepatitis-free future closer than ever.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
bloodborne viruses, HBV, HCV, HDV, liver, Viral hepatitis
in
GERMS
volume
15
issue
3
pages
11 pages
publisher
European Academy of HIV/AIDS and Infectious Diseases
external identifiers
  • scopus:105026343635
  • pmid:41334128
ISSN
2248-2997
DOI
10.18683/germs.2025.1473
language
English
LU publication?
yes
id
ee806383-203c-4c3e-b915-cceb2cf454b2
date added to LUP
2026-02-16 14:12:48
date last changed
2026-09-02 18:16:20
@article{ee806383-203c-4c3e-b915-cceb2cf454b2,
  abstract     = {{<p>Hepatitis B virus (HBV), hepatitis delta virus (HDV), and hepatitis C virus (HCV) remain leading drivers of chronic viral hepatitis, cirrhosis, hepatocellular carcinoma, and liver-related mortality. This ESCMID Study Group for Viral Hepatitis (ESGVH) narrative review summarizes recent advances and expert perspectives in the field. For HBV, emerging biomarkers such as quantitative HBs antigen, HBV RNA, and hepatitis B core-related antigen offer opportunities to refine monitoring and to individualize treatment. HDV epidemiology is evolving, and is being increasingly studied; in parallel, the approval of bulevirtide represents a major breakthrough in therapy, with further agents in the HDV pipeline. For HCV, direct-acting antivirals provide curative therapy and have made elimination a realistic goal, while identifying remaining gaps in diagnosis, linkage-to-care, and equitable access offers clear opportunities to accelerate progress. Together, these advances bring the goal of a hepatitis-free future closer than ever.</p>}},
  author       = {{Săndulescu, Oana and Matičič, Mojca and Garcia, Federico and Blomé, Marianne Alanko and Mondelli, Mario U. and Irving, William and Zidovec-Lepej, Snjezana and Widell, Anders and Şahin, Gülşen Özkaya}},
  issn         = {{2248-2997}},
  keywords     = {{bloodborne viruses; HBV; HCV; HDV; liver; Viral hepatitis}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{263--273}},
  publisher    = {{European Academy of HIV/AIDS and Infectious Diseases}},
  series       = {{GERMS}},
  title        = {{Evolving insights into viral hepatitis : Advances, evidence, and expert perspectives from the ESCMID Study Group for Viral Hepatitis (ESGVH) – Part 2: hepatitis B, C, and delta}},
  url          = {{http://dx.doi.org/10.18683/germs.2025.1473}},
  doi          = {{10.18683/germs.2025.1473}},
  volume       = {{15}},
  year         = {{2025}},
}